A button will appear below the video, once finished viewing, that will advance you to the post-test.

In this module, the sphingosine 1-phosphate (S1P) receptor modulator ponesimod is discussed in the context of emerging therapies. However, it has since been approved by the US FDA for the treatment of relapsing forms of MS. Please refer to its prescribing information for details about its administration, adverse effects, and monitoring requirements (https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213498s001lbl.pdf).